| Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. | |
| | |
MedLine Citation:
|
PMID: 18060250 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The translation of fundamental science-based constructs to the preemptive identification and optimal management of individuals with or those at risk for thrombotic disorders of the cardiovascular system has taken a step closer to being realized with the development of molecular technologies that include nucleic acid aptamers and their complimentary oligonucleotide antidotes. Herein, we summarize our experience with factor IX and von Willebrand factor aptamers, and introduce the era of antithrombotic pharmacobiologic therapy. |
| | |
Authors:
|
R C Becker; S Oney; K C D Becker; C P Rusconi; B Sullenger |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Hämostaseologie Volume: 27 ISSN: 0720-9355 ISO Abbreviation: Hamostaseologie Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2007-12-06 Completed Date: 2008-01-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8204531 Medline TA: Hamostaseologie Country: Germany |
Other Details:
|
Languages: eng Pagination: 378-82 Citation Subset: IM |
Affiliation:
|
Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA. becke021@mc.duke.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Coagulation Factors
/
physiology Clinical Trials as Topic Fibrinolytic Agents / therapeutic use* Humans Randomized Controlled Trials as Topic Reproducibility of Results Thrombolytic Therapy |
| Chemical | |
Reg. No./Substance:
|
0/Blood Coagulation Factors; 0/Fibrinolytic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Extracellular RNA. A new player in blood coagulation and vascular permeability.
Next Document: Prevalence of bone mineral disease among adolescents with cystic fibrosis.